Zoetis Inc - Asset Resilience Ratio
Zoetis Inc (ZTS) has an Asset Resilience Ratio of 12.20% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ZTS liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Zoetis Inc's Asset Resilience Ratio has changed over time. See Zoetis Inc (ZTS) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Zoetis Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Zoetis Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $1.72 Billion | 12.2% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $1.72 Billion | 12.20% |
Asset Resilience Insights
- Moderate Liquidity: Zoetis Inc has 12.20% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Zoetis Inc Industry Peers by Asset Resilience Ratio
Compare Zoetis Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Zoetis Inc (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Zoetis Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 13.96% | $1.99 Billion | $14.24 Billion | -0.32pp |
| 2023-12-31 | 14.27% | $2.04 Billion | $14.29 Billion | -9.69pp |
| 2022-12-31 | 23.97% | $3.58 Billion | $14.93 Billion | -1.08pp |
| 2021-12-31 | 25.05% | $3.48 Billion | $13.90 Billion | -1.43pp |
| 2020-12-31 | 26.48% | $3.60 Billion | $13.61 Billion | +9.71pp |
| 2019-12-31 | 16.77% | $1.94 Billion | $11.54 Billion | +0.99pp |
| 2018-12-31 | 15.78% | $1.70 Billion | $10.78 Billion | -2.43pp |
| 2017-12-31 | 18.22% | $1.56 Billion | $8.59 Billion | +8.71pp |
| 2016-12-31 | 9.50% | $727.00 Million | $7.65 Billion | -- |
| 2015-12-31 | 0.00% | $0.00 | $7.91 Billion | -- |
| 2014-12-31 | 0.00% | $0.00 | $6.59 Billion | -- |
| 2013-12-31 | 0.00% | $0.00 | $6.56 Billion | -- |
About Zoetis Inc
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and… Read more